1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Inno Models

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2020

Location

Beijing China

Primary Industry

Biotechnology

About

Based in Beijing, China and established in 2020, Inno Models is a CRO provider of oncology and tumor immune pharmacodynamic evaluation that focuses on tumor immune pharmacodynamics research. In February 2021, Inno Models raised an undisclosed amount in angel funding from new investors Dalton Venture and Yusen Capital. Inno Models is dedicated to the development of next-generation pharmacodynamic in vitro and experimental animal models for tumor and tumor immunity, and has developed a variety of humanized tumor immune pharmacodynamic platforms and immune system-PDX dual-derived platforms based on a new generation of NIG heavily combined immunodeficient mice. The company has established a second-generation PBMC immune system humanization model and a second-generation PDX human tumor xenograft model, which can reconstitute a variety of immune cells including T cells, NK cells and DC cells.
Current Investors
Dalton Venture, Yusen Capital, Zhongguancun Co-Innovative Fund Management

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.